Pancragen

1. Overview

Pancragen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Trp (KEDW) and an approximate molecular weight of 576 Da. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it was derived from bovine pancreatic tissue extracts and is classified as a pancreatic bioregulator peptide [8][9].

Among the Khavinson peptide bioregulators, Pancragen is one of the most extensively studied, with published research spanning in vitro cell cultures, streptozotocin-diabetic rat models, aged rhesus monkey studies, and a limited human clinical study in elderly patients with type 2 diabetes mellitus [1][2][3][4][5]. This breadth of evidence -- while still originating predominantly from Khavinson's group -- places Pancragen ahead of most other Khavinson peptides in terms of research depth.

The peptide's primary researched effect is the restoration of age-related pancreatic dysfunction, including normalization of blood glucose levels, insulin secretion, and glucose tolerance [1][2][4][5]. At the molecular level, Pancragen upregulates key transcription factors governing pancreatic cell differentiation, including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4 [3][6]. These transcription factors orchestrate the development and maintenance of both exocrine acinar cells and endocrine islet cells, making them pharmacologically significant targets for metabolic disease [3][6].

Sequence

Lys-Glu-Asp-Trp (KEDW)

Molecular Weight

576.25 g/mol (as amidated form)

Type

Synthetic tetrapeptide (Khavinson pancreatic bioregulator)

Source

Synthetic analog of peptide isolated from bovine pancreatic tissue

Mechanism

Upregulation of pancreatic transcription factors (Pdx1, Pax6, Foxa2, Nkx2.2); epigenetic regulation of islet and acinar cell differentiation

Routes Studied

Intramuscular (primates), oral (rats, humans), in vitro (cell cultures)

FDA Status

Not approved; no clinical trials registered on ClinicalTrials.gov

Related Peptides

Epithalon (AEDG), Pinealon (EDR), Livagen (KEDA)

2. Mechanism of Action

Pancragen operates through epigenetic regulation of pancreatic gene expression, with its effects primarily characterized through modulation of transcription factors critical for pancreatic cell differentiation and maintenance.

Upregulation of Pancreatic Transcription Factors

The central mechanistic finding for Pancragen comes from a 2013 study in human embryonic pancreatic cell cultures [3]. Pancragen stimulated expression of differentiation factors for both major pancreatic cell lineages:

Acinar cell differentiation factors:

• Pdx1 (pancreatic and duodenal homeobox 1) -- a master regulator of pancreatic development and beta-cell function
• Ptf1a (pancreas-specific transcription factor 1a) -- essential for exocrine pancreas specification

Islet of Langerhans differentiation factors:

• Pdx1 -- also critical for beta-cell maturation and insulin gene expression
• Pax6 (paired box gene 6) -- required for alpha-cell differentiation and glucagon expression
• Pax4 (paired box gene 4) -- directs beta-cell and delta-cell specification
• Foxa2 (forkhead box A2) -- regulates insulin secretion and glucose metabolism
• Nkx2.2 (NK2 homeobox 2) -- essential for beta-cell terminal differentiation

These effects were observed in both young and aged cultures, with tissue-specific stimulation more pronounced in older cultures [3]. This age-dependent amplification is consistent with the Khavinson bioregulator theory that these peptides primarily restore age-depleted signaling rather than producing supraphysiological effects [6][8].

In a more recent study, Pancragen specifically stimulated expression of differentiation factors CXCL12 and Hoxa3 in human embryonic pancreatic cells, with effects most pronounced in aged cultures [3][6].

Epigenetic Regulation

Like other Khavinson peptides, Pancragen is proposed to penetrate cell membranes and nuclear membranes due to its small molecular weight, interacting directly with DNA and chromatin to modulate gene expression [7][12]. The peptide's ability to upregulate specific transcription factors suggests it alters the epigenetic landscape of pancreatic cells, potentially through modifications to histone proteins or DNA methylation patterns that increase accessibility of differentiation gene promoters [7][13].

Endothelioprotective Effects

Beyond pancreatic endocrine function, Pancragen demonstrated endothelioprotective effects in diabetic rat models [1]. Intramuscular administration normalized adhesion of mesenteric capillary endothelium, suggesting protective effects on the vascular complications of diabetes, though capillary permeability itself was not modified [1].

3. Researched Applications

Experimental Diabetes Mellitus (Rats)

Evidence level: Preclinical (animal study)

In the first published animal study (2007), effects of pancragen were evaluated in Wistar rats with streptozotocin-induced diabetes mellitus [1]. Oral pancragen produced a pronounced hypoglycemic effect during the treatment period, while intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium [1]. These results demonstrated both homeostatic (glucose-lowering) and endothelioprotective effects during the early period of experimental diabetes [1].

Age-Related Glucose Intolerance (Primates)

Evidence level: Preclinical (primate studies)

Two primate studies provide the strongest preclinical evidence for Pancragen.

In a 2015 study, pancragen was administered to old female rhesus monkeys (20-25 years) and demonstrated a decrease in basal blood glucose levels and normalization of insulin and C-peptide levels, suggesting a recovering effect on age-related glucose intolerance [4].

A 2017 comparative study directly compared pancragen (0.05 mg/animal/day IM for 10 days) to glimepiride (4 mg/animal/day orally for 10 days) in 9 old rhesus monkey females [5]. Both agents decreased basal blood glucose, but pancragen also normalized insulin and C-peptide levels, while glimepiride produced a more pronounced but delayed hypoglycemic effect and stimulated C-peptide secretion without significantly affecting insulin secretion [5]. The authors concluded that pancragen was effective and safe for correction of age-related endocrine pancreatic dysfunction [5].

Earlier work by Goncharova et al. (2004, 2005) had established the age-related decline in pancreatic endocrine function in rhesus monkeys, providing the physiological context for these pancragen studies [10][11][17].

Type 2 Diabetes in Elderly Humans

Evidence level: Limited clinical data

The only published human study was conducted by Korkushko, Khavinson et al. (2011) at the Institute of Gerontology, Ukrainian Academy of Medical Sciences [2]. The study examined 30 healthy elderly individuals and 33 patients with type 2 diabetes mellitus:

• In patients with DM2, pancragen significantly decreased fasting glucose levels and glucose during standard glucose tolerance testing
• Plasma concentrations of insulin and the insulin resistance index (HOMA-IR) were reduced
• Nocturnal melatonin production was found to be 70% lower in DM2 patients compared to age-matched healthy individuals
• No changes in carbohydrate metabolism indices occurred in the control group receiving no pancragen

The authors proposed that disturbances in the melatonin-producing function of the pineal gland contribute to insulin resistance development in the elderly, and that pancragen represents a promising approach to insulin resistance correction [2]. However, this study was not randomized, not blinded, and conducted at a single center affiliated with Khavinson's research network.

Pancreatic Cell Differentiation

Evidence level: In vitro

The 2013 cell culture study demonstrated that pancragen stimulates differentiation of both acinar and islet cells through upregulation of lineage-specific transcription factors [3]. This differentiation-inducing effect has been proposed as the underlying mechanism for pancragen's anti-diabetic and anti-inflammatory properties, as impaired pancreatic cell differentiation and renewal contribute to age-related decline in both exocrine and endocrine pancreatic function [3][6].

4. Clinical Evidence Summary

5. Dosing in Research

Notes on Dosing

The primate studies used intramuscular injection at 0.05 mg/animal/day for 10 consecutive days [5], while the rat study tested both oral and intramuscular routes [1]. The human study did not fully specify the dose and duration in available English-language abstracts [2]. Commercially available preparations are typically marketed as oral capsules (200 ug per capsule) or injectable vials (20 mg), with anecdotal protocols of 1-2 capsules daily for 20-30 days. These protocols have not been validated in dose-finding studies.

6. Comparison with Conventional Antidiabetic Agents

The 2017 primate study provides a direct comparison between pancragen and glimepiride, a sulfonylurea-class antidiabetic drug [5]:

Glimepiride acts by stimulating insulin secretion from pancreatic beta cells through binding to sulfonylurea receptors on the beta-cell membrane. It produced a more pronounced hypoglycemic effect but with delayed onset, and stimulated C-peptide secretion without significantly affecting insulin levels [5]. Sulfonylureas carry established risks of hypoglycemia and beta-cell exhaustion with long-term use.

Pancragen produced a more moderate glucose-lowering effect but normalized both insulin and C-peptide levels, suggesting restoration of physiological pancreatic function rather than forced insulin secretion [5]. The authors characterized pancragen's mechanism as "recovering" rather than "stimulating," consistent with the bioregulator paradigm of restoring normal function rather than overriding it [5].

This comparison, while suggestive, involved only 9 animals and has not been replicated in human studies.

7. Safety and Side Effects

Published Safety Data

• In the primate studies, pancragen was described as effective and safe, with no adverse events reported [4][5]
• The comparison with glimepiride suggested a more favorable safety profile for pancragen, without the delayed hypoglycemic effects observed with the sulfonylurea [5]
• In the human study, no adverse events were specifically reported [2]
• In the rat diabetes study, no treatment-related toxicity was noted [1]

Safety Gaps

• No formal toxicology studies meeting ICH/FDA regulatory standards have been published
• No long-term safety data in any species
• No reproductive or developmental toxicity studies
• No drug interaction studies (particularly relevant given potential interactions with insulin, sulfonylureas, or metformin)
• No pharmacokinetic studies defining oral bioavailability, half-life, or metabolism
• The effects of sustained upregulation of pancreatic transcription factors on cancer risk (particularly pancreatic cancer) have not been evaluated
• All safety data originate from the Khavinson research network

8. Regulatory Status

Pancragen is not approved by the FDA, EMA, or any major Western regulatory agency. No clinical trials are registered on ClinicalTrials.gov. It is available as a research peptide and as a dietary supplement in some jurisdictions, but it is not a licensed pharmaceutical product. In Russia, the parent pancreatic polypeptide extract has been used in clinical settings, and pancragen is available as a registered dietary supplement under the Khavinson peptide product line [16].

9. Khavinson Bioregulator Context

Pancragen occupies a specific position within the Khavinson bioregulator theory as the pancreas-targeted peptide. According to this framework, each organ produces characteristic short peptides that regulate its own function, and age-related decline in these peptides contributes to organ dysfunction [8][9]. Pancragen's relationship to the pineal-pancreatic axis is noteworthy: the human study found that elderly DM2 patients had 70% lower nocturnal melatonin production, and earlier work by Goncharova et al. had shown that pineal peptides (including Epithalon) restore age-related disturbances in both pineal and pancreatic function [2][10]. This cross-organ interaction suggests that the pancreatic and pineal bioregulatory systems may be functionally linked.

10. Pharmacokinetics

Pancragen has more pharmacokinetic-relevant data than most Khavinson peptides, owing to its testing across multiple routes (oral, intramuscular) and species (rats, primates, humans). However, formal pharmacokinetic parameters remain unpublished.

In the rat diabetes study, oral Pancragen produced a "pronounced hypoglycemic effect," demonstrating that some biologically active component is absorbed from the gastrointestinal tract [1]. The intramuscular route in the same study normalized endothelial adhesion but did not modify capillary permeability, suggesting route-dependent pharmacodynamic differences [1].

In the primate study, intramuscular Pancragen at 0.05 mg/animal/day for 10 days normalized glucose, insulin, and C-peptide levels [5]. This provides a quantitative dose-exposure benchmark for the IM route in a species closely related to humans. The pancreas, as a well-vascularized organ with fenestrated endothelium in the islets of Langerhans, is theoretically accessible to systemically circulating peptides.

As a tetrapeptide of 576 Da, KEDW would undergo rapid proteolytic degradation in plasma. The tryptophan residue at the C-terminus may provide slight protease resistance compared to smaller amino acids, but no half-life data exist. The oral bioavailability needed to explain the hypoglycemic effect in rats has not been measured.

11. Dose-Response

Pancragen has more dose-relevant information than most Khavinson peptides, though a formal dose-response curve has not been published. Key data points include:

The primate study used 0.05 mg/animal/day IM for 10 days [5], which normalized glucose and insulin. This dose was compared to glimepiride at 4 mg/animal/day (80-fold higher by weight), suggesting that Pancragen may be effective at substantially lower doses than conventional antidiabetic agents, assuming equivalent bioavailability. The cell culture study showed differentiation factor upregulation more pronounced in aged than young cultures [3], suggesting that the dose-response relationship may be age-dependent.

The human study in elderly DM2 patients reported significant glucose and insulin effects but did not fully specify the dose in available English-language abstracts [2]. This prevents dose-response analysis from the clinical data.

No studies have compared different Pancragen doses for the same endpoint. Whether higher doses produce greater transcription factor upregulation, greater glucose lowering, or a plateau effect is unknown. The potential for hypoglycemia at higher doses -- a critical safety parameter for any glucose-lowering agent -- has not been characterized.

12. Comparative Effectiveness

Pancragen (KEDW) vs. Glimepiride

The 2017 primate study provides the only direct comparison between a Khavinson peptide and a conventional pharmaceutical [5]. Both agents decreased basal blood glucose, but their mechanisms and effect profiles differed: glimepiride forced insulin secretion via sulfonylurea receptor binding, while Pancragen normalized insulin and C-peptide levels through proposed transcription factor modulation. Pancragen lacked the delayed hypoglycemic effect observed with glimepiride, suggesting a potentially safer glucose-lowering profile [5]. However, this comparison involved only 9 animals and has not been replicated.

Pancragen vs. Other Khavinson Peptides

Pancragen is among the best-characterized Khavinson peptides, with evidence spanning cell culture through primate studies and limited human data. Only Epithalon, Thymalin, and Cortexin have comparable or greater evidence breadth. Pancragen's unique advantage is the depth of transcription factor characterization (Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, Pax4) [3][6], providing the most detailed molecular mechanism among Khavinson synthetic peptides.

Pancragen vs. GLP-1 Receptor Agonists

Modern incretin-based therapies (semaglutide, tirzepatide) represent the current frontier of diabetes and metabolic disease treatment, with massive RCT evidence for glucose control, weight loss, cardiovascular risk reduction, and kidney protection. Pancragen proposes a fundamentally different mechanism (transcription factor-mediated pancreatic cell differentiation) at a different evidence tier (one small uncontrolled human study). No comparison is possible given the vast evidence gap.

13. Enhanced Safety

Pancragen has the broadest species-level safety data among Khavinson synthetic peptides, with no adverse events reported across rat, primate, and human studies [1][2][4][5]. The primate comparison with glimepiride specifically highlighted a more favorable safety profile for Pancragen, lacking the delayed hypoglycemic effects associated with the sulfonylurea [5].

The absence of hypoglycemia in published studies is encouraging for a glucose-lowering agent, as hypoglycemia is the most common and dangerous acute adverse effect of antidiabetic medications. The proposed "normalizing" mechanism (restoring pancreatic transcription factor expression rather than forcing insulin secretion) provides a theoretical rationale for this safety advantage, though it has not been validated through provocative testing or long-term monitoring.

The sustained upregulation of pancreatic transcription factors (particularly Pdx1 and Pax6) raises a specific oncological consideration. Pdx1 has been implicated in pancreatic ductal adenocarcinoma progression, and Pax6 has context-dependent oncogenic potential. Whether chronic upregulation of these factors by Pancragen could promote pancreatic neoplasia has not been evaluated. No carcinogenicity studies have been conducted.

No drug interaction studies exist. This is particularly relevant for patients taking insulin, sulfonylureas, metformin, SGLT2 inhibitors, or GLP-1 receptor agonists, where additive glucose-lowering effects could precipitate hypoglycemia. The potential for interaction with the melatonin-insulin resistance axis identified in the human study [2] adds another layer of complexity.

14. Related Peptides

See also: Epithalon, Pinealon, Livagen, Ovagen, Prostamax

15. References

1. [1] Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO. (2007). Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine. DOI PubMed
2. [2] Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. (2011). Prospects of using pancragen for correction of metabolic disorders in elderly people. Bulletin of Experimental Biology and Medicine. DOI PubMed
3. [3] Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO. (2013). Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bulletin of Experimental Biology and Medicine. DOI PubMed
4. [4] Goncharova ND, Khavinson VKh, Vengerin AA. (2015). Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Advances in Gerontology. PubMed
5. [5] Goncharova ND, Khavinson VKh. (2017). Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys. Advances in Gerontology. PubMed
6. [6] Khavinson VKh, Linkova NS, Diatlova AS, Trofimova SV. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports. DOI PubMed
7. [7] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
8. [8] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
9. [9] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
10. [10] Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. (2005). Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. DOI PubMed
11. [11] Goncharova ND, Khavinson VKh, Lapin BA. (2004). Age-associated changes in hormonal function of the pancreas and regulation of blood glucose in monkeys. Bulletin of Experimental Biology and Medicine. DOI
12. [12] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
13. [13] Khavinson VKh, Linkova NS, Kvetnoy IM. (2015). Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Bulletin of Experimental Biology and Medicine. PubMed
14. [14] Khavinson VKh, Lezhava TA. (2023). Epigenetic modification under the influence of peptide bioregulators on old chromatin. Advances in Gerontology. PubMed
15. [15] Khavinson VKh, Linkova NS, Kvetnoy IM. (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
16. [16] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klinicheskaia Meditsina (Mosk).
17. [17] Goncharova ND, Khavinson VKh, Vengerin AA. (2004). Peptide correction of age-related hormonal dysfunction of the pancreas in monkeys. Bulletin of Experimental Biology and Medicine. PubMed